This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Hematology				
Hemophilia	Factor VIII	<p>Mouse studies suggest phosphatidylserine-bound factor VIII could help treat patients with hemophilia A. Patients with hemophilia A lack factor VIII and often develop an antibody response against factor VIII replacement therapy that limits therapeutic benefit. In a mouse model for hemophilia A, pretreatment with factor VIII linked to phosphatidylserine (FVIII-PS) led to a decreased anti-factor VIII antibody response compared with pretreatment using free factor VIII. Next steps include optimizing the FVIII-PS dosage and conducting clinical tests.</p> <p>At least nine companies have factor VIII-based compounds in development stages ranging from Phase II trials to market for treating hemophilia.</p> <p>SciBX 6(22); doi:10.1038/scibx.2013.548 Published online June 6, 2013</p>	Patent application filed; available for licensing	<p>Gaitonde, P. <i>et al. J. Biol. Chem.</i>; published online May 6, 2013; doi:10.1074/jbc.C112.396325</p> <p>Contact: Sathy V. Balu-Iyer, University at Buffalo, Buffalo, N.Y. e-mail: svb@buffalo.edu</p>